问题 › 我的业务到底值多少钱？ › 健康科技与数字健康
数字健康估值更看风险收入份额能否持续，而非表面 ARR。 数字健康公司面临结构性难题：风险收入比例签署速度快于公司验证自身能否承担的周期——12 个月测量窗口对 11 个月销售周期。任何可信答案都需同时纳入风险收入份额与参与率，而这两项通常分属不同系统，导致内部分析止步于此。
数字健康估值更看风险收入份额能否持续，而非表面 ARR。 数字健康公司面临结构性难题：风险收入比例签署速度快于公司验证自身能否承担的周期——12 个月测量窗口对 11 个月销售周期。任何可信答案都需同时纳入风险收入份额与参与率，而这两项通常分属不同系统，导致内部分析止步于此。
创始人按当前收益定价。收购方评估接手合同后风险收入份额能保留多少，这解释了为何两家 ARR 相同的企业拿到的报价可能差异很大。
影响倍数的因素包括风险收入占比、支撑归因结果的参与率、客户流失率，以及扣除 PMPM 成本后的毛利率。这些因素对倍数的影响，远超多一美元利润对基数的贡献。
真正的工作不是证明当前收益，而是找出哪项因素正在压低倍数，以及能否在启动流程前改善它。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 风险收入份额上升，而结果测量窗口仍固定为十二个月，对应十一个月的销售周期。
✓ 大量归因结果仍依赖 CEO 或创始人个人关系，而非可重复的运营流程。
✓ 多数收入集中在流失率上升或参与率下降的客户上，直接影响 PMPM 与毛利率。
通常会让情况更糟的做法。 在出售前一年提高毛利率，却未触动风险收入份额和参与率，这对价值的提升通常不及降低其中一项质量风险。
It is for you if you run or finance a digital health company and you are within a few years of a transaction and have never had the earnings normalised. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 增长组合框架, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
行业区间容易找到，却是最没用的部分。你落在区间哪个位置，取决于集中度、复购性、所有者依赖度和利润防御性。
若目标是提升倍数，需要两到三年，因为这才是 recurring revenue 和降低所有者依赖在数字中显现所需的时间。
取决于买家。财务买家为 durable cash flow 买单；战略买家为业务对其自身地位的作用买单。清楚你面对的是哪类买家，会改变该修复的内容。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית